SoniVie
SoniVie is a medical device company dedicated to developing innovative ultrasound-based denervation systems for treating hypertensive disorders, including resistant hypertension and pulmonary hypertension. Founded in 2014, the company has achieved significant milestones including FDA Breakthrough Device Designations, clinical trials, and a pending acquisition by Boston Scientific. Their flagship product, TIVUS, employs high-frequency ultrasound technology to safely and effectively perform renal and pulmonary denervation procedures, aiming to improve patient outcomes and address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Patents
Devices and methods for reducing parasympathetic nerve activity in patients with a respiratory syndrome
US-12318638-B2
View Details
Devices and methods for reducing parasympathetic nerve activity in patients with a respiratory syndrome
US-12318638-B2
View DetailsProducts
Intravascular ultrasound denervation system (catheter-based)
A catheter-based intravascular system that delivers high-frequency non-focused ultrasonic energy to ablate perivascular nerves while maintaining blood flow through the treated vessel; developed for renal and pulmonary denervation procedures.
Intravascular ultrasound denervation system (catheter-based)
A catheter-based intravascular system that delivers high-frequency non-focused ultrasonic energy to ablate perivascular nerves while maintaining blood flow through the treated vessel; developed for renal and pulmonary denervation procedures.
Services
Planning and operating multicenter clinical studies (IDE-approved pilot and pivotal studies), providing site initiation and enrollment support, study monitoring, and clinical data collection for regulatory submissions.
Development and consolidation of intravascular ultrasound denervation platform technologies and associated intellectual property to enable multi-indication development.
Planning and operating multicenter clinical studies (IDE-approved pilot and pivotal studies), providing site initiation and enrollment support, study monitoring, and clinical data collection for regulatory submissions.
Development and consolidation of intravascular ultrasound denervation platform technologies and associated intellectual property to enable multi-indication development.
Expertise Areas
- Renal denervation procedures and clinical development
- Pulmonary artery denervation for pulmonary hypertension
- Platform development for multiorgan denervation (including lung denervation)
- Clinical trial design and global trial execution (IDE and pivotal studies)
Key Technologies
- Intravascular therapeutic ultrasound
- High-frequency non-focused ultrasound ablation
- Catheter-based nerve ablation
- Radial rapid-exchange catheter design (4Fr)
News & Updates
Acquisition to expand interventional cardiology therapies with ultrasound-based renal denervation for hypertension.
SoniVie announced the appointment of Raymond W. Cohen as its chairman of the board.
SoniVie announced pilot results, FDA approval for the global THRIVE study, and progress in renal denervation.
SoniVie announced the last patient was treated in the REDUCED-1 pilot study for hypertension.
The company secured funding to support clinical and regulatory milestones for TIVUS.
Details about the acquisition of SoniVie by Boston Scientific to expand interventional cardiology therapies.
Acquisition to expand interventional cardiology therapies with ultrasound-based renal denervation for hypertension.
SoniVie announced the appointment of Raymond W. Cohen as its chairman of the board.
SoniVie announced pilot results, FDA approval for the global THRIVE study, and progress in renal denervation.
SoniVie announced the last patient was treated in the REDUCED-1 pilot study for hypertension.
The company secured funding to support clinical and regulatory milestones for TIVUS.
Details about the acquisition of SoniVie by Boston Scientific to expand interventional cardiology therapies.